News summary

Risk stratification in early non-ischaemic cardiomyopathy: The interplay of genetics and cardiac imaging

Source: Frontiers - Health • Published: 24 Sept 2026, 00:00

Summarized by Masters of Longevity from Frontiers - Health.

Risk stratification in early non-ischaemic cardiomyopathy, examining how genetics and cardiac imaging may guide personalized prevention; a concise review to orient clinicians and researchers.

Risk stratification in early non-ischaemic cardiomyopathy: The interplay of genetics and cardiac imaging
Key Takeaways
  • Left ventricular ejection fraction alone inadequately predicts arrhythmic risk in early dilated and non-dilated cardiomyopathies.
  • Late gadolinium enhancement on cardiovascular magnetic resonance identifies fibrosis-based substrates linked to higher arrhythmic risk.
  • Integrating genotype-specific phenotyping with imaging improves personalized risk stratification for sudden cardiac death prevention.
Read the full article at Frontiers - Health ↗

Continue exploring

Recommended MoL Picks

MoL PickApoB: The cholesterol signal LDL can missIn longevity medicine, the useful biomarkers are not always the exotic ones. ApoB is a relatively simple blood test that can sharpen cardiovascular prevention when LDL-C looks reassuring but particle burden remains high.MoL PickSemaglutide Extended Lifespan in Mice. What Would Make It a Human Longevity Drug?A new animal study sharpens an important question: when do benefits in a particular disease become evidence for a longer, healthier life?MoL PickThe Next Obesity-Drug Race Is About What Weight You LoseRegeneron’s myostatin and activin A antibodies point to a sharper question for the GLP-1 era: not whether people can lose more weight, but whether medicine can preserve the tissue that makes weight loss healthier.